EGRX - Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Eagle Pharmaceuticals Inc. (EGRX) | Benzinga

SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) securities between August 8, 2023 and November 28, 2023. Eagle Pharmaceuticals is an integrated pharmaceutical company engaged in research and development, clinical, manufacturing and commercial sales. The Company has several commercialized products, including PEMFEXY, which is metabolic inhibitor used in combination with chemotherapy for the initial treatment of certain genomic tumor aberrations.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue

According to the complaint, on November 9, 2023, before the market opened, Eagle Pharmaceuticals announced that it would not release its third quarter 2023 results that day (as had been expected) because the Company "requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY® prior to filing its Form 10-Q." The Company also disclosed it "expects to revise its previously disclosed 2023 full year guidance downward." On this ...

EGRX)>Full story available on Benzinga.com